Stocks
Vertex Pharmaceuticals IncorporatedVRTX
NASDAQHealthcareBiotechnology$469.34-1.84%
A biotechnology company focused on developing and commercializing therapies for serious diseases, with a primary concentration in cystic fibrosis. Its portfolio of CF treatments generates the majority of revenue, supporting expansion into gene-editing and cell therapies for conditions including sickle cell disease, beta thalassemia, and type 1 diabetes. Investors closely monitor its pipeline diversification, regulatory milestones, and the durability of its cystic fibrosis franchise, which underpins cash flow and long-term growth expectations.
Market Cap: $119.2B52W Range: $362.50 – $517.20
Congressional Interest in Vertex Pharmaceuticals Incorporated (VRTX)
15 members of Congress have disclosed 44 trades in Vertex Pharmaceuticals Incorporated (VRTX), a Healthcare company. The buy/sell breakdown shows 22 purchases versus 22 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
44
Unique Politicians
15
Buys
22
Sells
22
Who in Congress Is Trading VRTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-06-07 | Vern Buchanan | buy | $1K – $15K |
| 2021-01-28 | Peter Meijer | sell | $1K – $15K |